Other Stories

Pfizer's COVID-19 trial vaccine more than 90% effective: report Updated: 2020-11-10 13:25:08 KST

With over 50 million COVID-19 cases reported so far, the world is in dire need of a working vaccine.
The latest announcement by Pfizer is a welcome one, as the American biopharmaceutical company announced Monday that its COVID-19 vaccine may be more than 90-percent effective, based on its early and incomplete test results, which nevertheless bring some much-needed optimism.
The news comes from an analysis of a study involving over 43-thousand volunteers.
Forty-two percent of whom come from "diverse backgrounds".
Each participant received two injections, 21 days apart.
Pfizer and its Germany partner BioNTech say the results from 94 evaluable cases of COVID-19 show the vaccine is more than 90-percent effective, much higher than the U.S. FDA minimum effectiveness bar of 50-percent.
The vaccine is the first in development to have data proving to exceed the minimum.
With the announcement, WHO chief Tedros Adhanom Ghebreyesus took to Twitter on Monday, calling the results "encouraging", while sending his "salute" to scientists around the world who are developing vaccines.
The WHO's senior advisor Bruce Aylward, while addressing the WHO's annual ministerial assembly, also called Pfizer's phase-three trial "very positive".
Tedros believes a COVID-19 vaccine may be rolled by March next year to the most vulnerable, and could fundamentally change the course of the pandemic, which has so far killed more than 1.26 million people worldwide.
Lee Seung-jae, Arirang News.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.